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Controlled Safety Study of a Hemoglobin-Based Oxygen
Carrier, DCLHb, in Acute Ischemic Stroke
Ritu Saxena, MD; Annemarie D. Wijnhoud; Herwig Carton, MD; Werner Hacke, MD;
Markku Kaste, MD; Robert J. Przybelski, MD; Kathleen N. Stern, PhD; Peter J. Koudstaal, MD
Background and Purpose—Diaspirin cross-linked hemoglobin (DCLHb) is a purified, cell-free human hemoglobin
solution. In animal stroke models its use led to a significant reduction in the extent of brain injury. The primary objective
of this study was to evaluate the safety of DCLHb in patients with acute ischemic stroke.
Methods—DCLHb or saline was administered to 85 patients with acute ischemic stroke in the anterior circulation, within
18 hours of onset of symptoms, in a multicenter, randomized, single-blind, dose-finding, controlled safety trial,
consisting of 3 parts: 12 doses of 25, 50, and 100 mg/kg DCLHb over 72 hours.
Results—DCLHb caused a rapid rise in mean arterial blood pressure. The pressor effect was not accompanied by
complications or excessive need for antihypertensive treatment. Two patients in the 100 mg/kg group had adverse events
that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic
insufficiency. Multivariate logistic regression analysis showed that a severe stroke at baseline and treatment with
DCLHb (OR, 4.0; CI, 1.4 to 12.0) were independent predictors of a worse outcome (Rankin Scale score of 3 to 6) at
3 months.
Conclusions—Outcome scale scores were worse in the DCLHb group, and more serious adverse events and deaths
occurred in DCLHb-treated patients than in control patients. We recommend that additional safety studies be performed,
preferably with a second generation, genetically engineered hemoglobin. (Stroke. 1999;30:993-996.)
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Diaspirin cross-linked hemoglobin (DCLHb) is a cell-free, hemoglobin-based oxygen-carrying solution. In
animal stroke models, hemodilution with DCLHb induced a
hypertensive response and resulted in significant reductions
in the extent of the brain injury.1,2 Hypertension has been
used in the treatment of stroke to increase blood flow, but its
use has not been widely adopted.3,4 The viscosity of DCLHb
is lower than that of whole blood, and it offers the potential
advantage of hemodilution without a decrease in oxygen
delivery.5 In addition, experimental data suggest that DCLHb
scavenges nitric oxide (NO),6 thereby inhibiting NO-related
neurotoxicity.
DCLHb is being developed as a hemoglobin therapeutic
for high-blood-loss surgery, sepsis, hemodialysis,7 cardiac
surgery, and trauma. In a phase 1 study in which healthy
volunteers received a single dose of DCLHb (25, 50, or 100
mg/kg), dose-dependent increases in mean arterial pressure
were reported. No significant adverse events or toxicity were
observed in the phase 1 study,8 in several phase 2 surgical and
ICU studies, or in the completed cardiac surgery study or
ongoing phase 3 perioperative study. However, a North
American study in trauma patients was recently terminated
prematurely because of higher mortality in the treatment
group, and enrollment in a European trauma study has been
suspended.9
The aim of our study was to assess the safety and
tolerability of repeated low-dose infusions of DCLHb started
within 18 hours of symptom onset in acute ischemic stroke
patients.
Subjects and Methods
The trial was conducted in compliance with the Declaration of
Helsinki and Good Clinical Practice for Trials on Medicinal Prod-
ucts. For participation, written informed consent from the patients or
their family was required. The participating centers were the neurol-
ogy departments in the university hospitals of Heidelberg, Helsinki,
Leuven, and Rotterdam. The Medical Ethics Committees approved
the protocol. Patients received all standard care and treatment,
including prophylactic medication such as acetylsalicylic acid and
heparin.
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Patients
Patients with clinical symptoms of an acute ischemic stroke in the
anterior circulation were eligible if they were aged .20 years, could
be treated within 18 hours after the start of symptoms, and were
likely to survive for at least 3 months. Patients had to be alert or
arousable by stimulation to obey, answer, or respond to verbal
commands. Brain CT scan had to be normal or compatible with a
recent infarction. Exclusion criteria were any major disabling disor-
der interfering with the assessments, pregnancy or lactation, an
evident hematologic cause of the symptoms, congestive heart failure
or acute myocardial infarction, systolic BP .230 mm Hg or diastolic
BP .130 mm Hg, renal or liver disease, spontaneous improvement
of symptoms by at least 2 grades on the modified Rankin Scale,10
and previous enrollment in this study or enrollment in another
investigational trial within 30 days. Eighty-five patients were en-
rolled between August 1994 and November 1996.
Drugs
DCLHb was derived from human erythrocytes and subjected to
rigorous viral inactivation and removal procedures.11 DCLHb was
prepared and provided by Baxter Healthcare Corp, Deerfield, Ill (lot
numbers 94A21AD11 through 95L08AD11).
Treatment Regimen
Patients were randomly assigned to DCLHb or saline (placebo) in a
1:1 ratio. The study was single blinded because of the prominent
color of the drug and the difficulty in manufacturing a proper
placebo. Three doses were tested: 25, 50, and 100 mg/kg 10%
DCLHb (n510, n510, and n520, respectively) or an equal volume
of saline (n545) every 6 hours for 72 hours (12 doses) intravenously
at a rate of 2 mL/min.
Assessments
Baseline assessment consisted of a medical history, general physical
and neurological examinations, ECG, CT scan, urinalysis, and
hematologic and biochemical tests. Neurological status was assessed
by means of the modified National Institutes of Health Stroke Scale
(NIHSS).12 Functional ability was scored by means of the Barthel
Activities of Daily Living Index13 and the modified Rankin scale.
Blood pressure and heart rate were measured every 15 minutes
during infusions with an automatic, oscillometric blood
pressure device.
The physical examination was repeated at days 3, 7, and 14 and at
the 3-month follow-up. The NIHSS was assessed at days 1, 3, and 14
and at 3 months. Rankin and Barthel scores were measured at day 14
and at 3 months. Safety was further monitored by regular blood tests,
urinalysis, repeat EKGs, 84-hour Holter monitoring, and repeat CT
and MRI scans.
Antibody titers to DCLHb were measured at the 3-month visit.
Statistics
Values are expressed as mean6SD unless otherwise indicated. The
Student unpaired t test, x2 test, or Fisher exact test were used as
appropriate. Regression analysis was used to identify factors inde-
pendently related to outcome at 3 months. A value of P,0.05 was
considered statistically significant.
Results
Patient characteristics are presented in the Table. The groups
were well matched with respect to all baseline variables,
although patients who received control treatment tended to
have experienced less severe strokes.
Adverse Events
Two patients had unexpected events, possibly related to
DCLHb. The first was a 65-year-old patient with a severe
stroke (NIHSS score of 23) and cardiomegaly; slightly
elevated SGOT, SGPT, and GGT; and obstructive breathing
at baseline. Blood pressure was 167/92. The patient received
5 doses of DCLHb of 80 mL each. Subsequently scleral
icterus, hypertension, fever, 2 episodes of pulmonary edema,
and cerebral edema developed, leading to death.
The other patient was a 53-year-old woman with a mod-
erately severe lacunar stroke (NIHSS score of 9) and a
medical history of untreated hypertension. Baseline examina-
tion showed a slightly elevated amylase (171 U/L). This
patient was treated with 12 doses of DCLHb. She developed
renal and pancreatic insufficiency, nausea, and anemia within
24 hours. All signs and symptoms resolved except for the
amylase, which was still asymptomatically elevated (215
U/L) at 3 months.
Minor adverse drug reactions independently related to
DCLHb occurred predominantly in the 100 mg/kg group.
Jaundice occurred in 0 of 10, 1 of 10, and 17 of 20 patients
in the 25, 50, and 100 mg/kg groups, respectively, versus 0 of
45 in the control group (P50.00); it resolved around day 5.
There was no associated hepatotoxicity, and it was considered
to be due to the extravasation of DCLHb and the rise in
bilirubin. Hemoglobinuria was found in 22 of 40 patients
Characteristics of Patients With Acute Ischemic Stroke
Randomized to DCLHb or Normal Saline
Characteristic Saline DCLHb P
Patients, n 45 40
Age, y 65615 68613 0.40
Sex
Female 22 (49) 24 (60) 0.42
Male 23 (51) 16 (40) 0.42
Stroke subtype
Cortical 32 (71) 26 (67) 0.84
Lacunar 13 (29) 12 (33) 0.84
Stroke side
Right 19 (42) 25 (63) 0.10
Left 26 (58) 15 (37) 0.10
Rankin score pre-infusion
2 2 (4) 2 (5) 0.69
3 16 (36) 7 (17) 0.10
4 11 (24) 17 (43) 0.12
5 16 (36) 14 (35) 0.86
Medical history
Angina pectoris 4 (9) 8 (20) 0.25
Atrial fibrillation 7 (16) 6 (15) 1.00
Diabetes mellitus 9 (18) 9 (23) 0.79
Hypercholesterolemia 1 (2) 1 (3) 1.00
Hypertension 18 (40) 20 (50) 0.48
Myocardial infarction 6 (13) 3 (8) 0.49
Smoking 19 (42) 12 (30) 0.35
Stroke 12 (27) 13 (33) 0.73
Systolic BP 155620 158624 0.52
Diastolic BP 85613 84613 0.72
Heart rate 75615 80613 0.18
Values in parentheses are percentages.
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versus 13 of 45 controls (P50.03). There was no associated
renal dysfunction, and the abnormalities resolved by day 7.
Laboratory Parameters
Dose-dependent increases of LDH, CPK, bilirubin, AST were
found. All laboratory abnormalities were clinically asymp-
tomatic and disappeared within a week. There was also a
dose-dependent rise in endothelin-1.14
All other laboratory measurements showed no statistically
significant difference between groups. At 3 months no
DCLHb antibodies were found.
Blood Pressure
DCLHb produced a rapid rise in mean arterial pressure,
which reached a maximum within 2 hours after the first
infusion. The blood pressure increased from 113614 at
baseline to 134620, versus 109616 mm Hg in controls. The
magnitude of the increases caused by the different doses was
similar, but the duration of the pressor was dose dependent.
The hypertensive reaction was not accompanied by clinical
signs of hypertensive encephalopathy, nor did the CT and
MRI-scans show occipital edema or brain swelling. Severe
hypertension requiring pharmacological intervention oc-
curred in 3 patients treated with DCLHb versus 3 in the saline
group.
Outcome
Outcome at 3 months was significantly worse in the treatment
group. Thirty-four patients (85%) had an unfavorable out-
come (Rankin score, 3 to 6) versus 23 (51%) in controls
(P50.002). Multivariate logistic regression analysis showed
that a severe stroke at baseline (Rankin score, 4 to 5;
P,0.001; OR, 20.9; CI, 4.1 to 102.4) and treatment with
DCLHb (P50.015; OR, 3.9; CI, 1.4 to 12.0) were indepen-
dent predictors of a worse outcome (Rankin score, 3 to 6).
Outcome was not related to the dose of DCLHb. The Barthel
Index and NIHSS showed similar results (Figure).
Discussion
We conducted a safety study on the use of DCLHb in patients
with acute ischemic stroke. DCLHb produced a rapid rise in
blood pressure. The duration of the effect was dose depen-
dent. The hypertensive effect was not accompanied by
complications such as hypertensive encephalopathy or hem-
orrhagic transformation of the infarction. Side effects that
were independently related to the use of DCLHb were
jaundice, hemoglobinuria, and some laboratory abnormali-
ties. These were all transient and clinically asymptomatic.
However, treatment with DCLHb was an independent
predictor of an unfavorable outcome at 3 months. The cause
of the worse outcome is unclear. We have recently reported
elevated ET-1 levels in response to DCLHb,14 which may
have contributed to the ischemic damage through the potent
vasoconstrictor effect of ET-1.15 However, there is also
evidence that a systemic increase in endothelin causes a
vasodilator effect in the brain.16 The dose-dependent increase
in ET-1 may have been promoted by the 72-hour duration of
treatment or by the treatment delay of 18 hours. Alternative
explanations of the worse outcome in DCLHb patients are the
role of chance in this small study; the imbalance, although not
statistically significant, of stroke severity at randomization; or
bias due to the single-blinded nature of the study. Further-
more, in analogy with other stroke treatments,17,18 it may be
beneficial to administer DCLHb immediately after the onset
of ischemia but harmful to give it during a later phase. In
most animal experiments, a highly favorable response was
found after a single, high-dose exchange transfusion of
DCLHb, either before or within 1 hour after initiation of
ischemia. Very recently, such high doses were found to be
safe in patients after they underwent coronary bypass
surgery.19
In conclusion, infusion of low doses of DCLHb over 3 days
adversely affected outcome in acute ischemic stroke patients,
and more serious adverse events and deaths occurred. A
difference in baseline stroke severity scores may have con-
tributed to this imbalance. We recommend that the safety of
a hemoglobin therapeutic in the treatment of stroke be further
explored, preferably using a second-generation, genetically
engineered hemoglobin. We suggest that treatment should
include a single high dose given earlier after stroke onset.
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